We believe that in the near future we will see not only the use of EV HOTTIP levels as recurrence tracking marker in NSCLC, but also in other tumors and the identification of more EV lncRNAs with clinical utility. This evidence concerns the gene HOTTIP and non-small cell lung carcinoma.